Humanin vs Dermorphin
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
HumaninRecovery & Repair
Dermorphin- Summary
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Half-Life
- ~4–8 hours (HNG)
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Admin Route
- SubQ
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- Research
- —
- —
- Typical Dose
- 2–8 mg
- Not established for human use; research doses vary widely
- Frequency
- 3–5 times per week
- Not established
- Key Benefits
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Side Effects
- Injection site irritation
- Limited human safety data available
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Stacks With
- —
- —